Related Experiment Video
Updated: Mar 29, 2026
08:25
Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
Published on: April 25, 2025
918
Detecting hepatocellular carcinoma in blood
1Department of Chemistry, Department of Biochemistry and Molecular Biology, and Institute for Biophysical Dynamics, The University of Chicago, Chicago, IL 60637, USA.
Cell Research
|November 25, 2015
Summary
Liquid biopsy offers a promising approach for early cancer detection. Wen et al. developed a novel method to identify blood-based biomarkers for early-stage liver cancer diagnosis.
Area of Science:
- Oncology
- Genomics
- Biomarker Discovery
Background:
- Liquid biopsy is a valuable tool for non-invasive cancer diagnosis and monitoring.
- Early detection of cancers like hepatocellular carcinoma (HCC) significantly improves patient outcomes.
- Identifying reliable biomarkers in cell-free DNA (cfDNA) is crucial for advancing liquid biopsy applications.
Purpose of the Study:
- To develop and validate a genome-wide profiling method for cell-free DNA (cfDNA).
- To identify novel, high-performance biomarkers in blood for the early detection of hepatocellular carcinoma (HCC).
Main Methods:
- Methylated CpG tandems amplification and sequencing (MCTA-seq) was employed to profile genome-wide methylation patterns in cfDNA.
- The study focused on hypermethylated CpG islands as potential cancer markers.
- Bioinformatic analysis was used to identify and validate candidate biomarkers.
Main Results:
- The MCTA-seq method successfully profiled genome-wide methylation in cfDNA.
- Several high-performance methylation markers were identified in blood plasma.
- These markers demonstrated potential for distinguishing early-stage HCC from healthy controls.
Conclusions:
- The developed MCTA-seq method is effective for genome-wide methylation profiling of cfDNA.
- The identified blood-based methylation markers show promise for the early detection of hepatocellular carcinoma.
- This approach could enhance non-invasive cancer diagnostics and patient management.
